Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 108Breast Neoplasms 72Carcinoma, Non-Small-Cell Lung 38Triple Negative Breast Neoplasms 29Squamous Cell Carcinoma of Head and Neck 18Neoplasm Metastasis 14Esophageal Squamous Cell Carcinoma 14Neoplasms 12Head and Neck Neoplasms 11Lung Neoplasms 10Stomach Neoplasms 9Gallbladder Neoplasms 8Cholangiocarcinoma 8Adenocarcinoma 8Melanoma 7Esophageal Neoplasms 7Biliary Tract Neoplasms 7Sarcoma 6Ovarian Neoplasms 5Inflammatory Breast Neoplasms 5Small Cell Lung Carcinoma 4Recurrence 4Pancreatic Adenocarcinoma 4Carcinoma, Ductal, Breast 4Uveal Melanoma 3Uterine Cervical Neoplasms 3Tongue Neoplasms 3Thymoma 3Pancreatic Diseases 3Nasopharyngeal Carcinoma 3

Interventions

Enoxaparin 3Tinzaparin 2Saline Solution 2Heparin, Low-Molecular-Weight 2Heparin 2Gemcitabine 2Fondaparinux 2Dalteparin 2130-nm albumin-bound paclitaxel 2palbociclib 1enoxaparin sodium 1edoxaban 1apixaban 1Warfarin 1Tranexamic Acid 1Sodium Chloride 1Sodium Bicarbonate 1Rivaroxaban 1Pentetic Acid 1PEGPH20 1Minocycline 1Ketoconazole 1Fluorodeoxyglucose F18 1Fluoridation 1Estramustine 1Enzyme-Linked Immunosorbent Assay 1Doxorubicin 1Docetaxel 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Thromboembolism × 130-nm albumin-bound paclitaxel × Clear all
NCT02921022 2025-11-26

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Memorial Sloan Kettering Cancer Center

Phase NA Active not recruiting
110 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

NCT05178628 2022-03-29

imPaCT-PRO

Institute of Molecular Medicine and Biomedical Research

Phase 3 Unknown
450 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡